Scynexis (NASDAQ:SCYX) insider Gonzalez David Angulo bought 14,790 shares of the business’s stock in a transaction dated Thursday, March 8th. The shares were acquired at an average cost of $1.69 per share, for a total transaction of $24,995.10. Following the purchase, the insider now owns 88,790 shares of the company’s stock, valued at approximately $150,055.10. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.
Gonzalez David Angulo also recently made the following trade(s):
- On Thursday, March 29th, Gonzalez David Angulo bought 6,000 shares of Scynexis stock. The shares were acquired at an average cost of $1.36 per share, for a total transaction of $8,160.00.
Shares of NASDAQ:SCYX opened at $1.28 on Friday. Scynexis has a 52-week low of $1.26 and a 52-week high of $2.93. The company has a market capitalization of $63.23, a P/E ratio of -1.27 and a beta of 0.26. The company has a current ratio of 4.43, a quick ratio of 4.43 and a debt-to-equity ratio of 0.48.
A number of large investors have recently made changes to their positions in SCYX. Dimensional Fund Advisors LP bought a new position in Scynexis in the third quarter worth approximately $264,000. Vanguard Group Inc. grew its stake in Scynexis by 6.0% in the second quarter. Vanguard Group Inc. now owns 868,394 shares of the company’s stock worth $1,554,000 after purchasing an additional 48,978 shares in the last quarter. Finally, GSA Capital Partners LLP grew its stake in Scynexis by 17.1% in the third quarter. GSA Capital Partners LLP now owns 206,900 shares of the company’s stock worth $499,000 after purchasing an additional 30,200 shares in the last quarter. 18.35% of the stock is currently owned by institutional investors.
Separately, ValuEngine raised Scynexis from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $7.75.
ILLEGAL ACTIVITY NOTICE: “Gonzalez David Angulo Buys 14,790 Shares of Scynexis (SCYX) Stock” was first posted by BBNS and is the sole property of of BBNS. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://baseballnewssource.com/2018/04/07/scynexis-inc-scyx-insider-buys-24995-10-in-stock/2038227.html.
SCYNEXIS, Inc, a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections.
Receive News & Ratings for Scynexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scynexis and related companies with MarketBeat.com's FREE daily email newsletter.